Latest Conference Articles

In a recent interview at the RSNA conference, Constance Lehman, M.D., Ph.D., discussed new research, which compared image-based AI for mammography versus breast density assessment in evaluating breast cancer risk.

The addition of ClearCEM to Mammomat B.brilliant devices reportedly enhances differentiation of suspicious areas in image reconstruction and facilitates improved accuracy with tomosynthesis-guided biopsies.

In a recent interview, Stamatia Destounis, M.D., discussed new research, which showed that over 20 percent of breast cancer was detected in women under 50 years of age and that 80 percent of these cases involved invasive breast cancer.

Reportedly the first MRI platform with a helium-free 3T magnet, the BlueSeal Horizon device offers a variety of AI-powered features as well as enhanced 3D image reconstruction.

In a study of over 13,000 patients who presented with knee pain, MRI data demonstrated a 20 percent higher prevalence of anterior cruciate ligament (ACL) tears in men than women.

Deep learning assessment of adrenal gland volume on computed tomography (CT) scans may provide an objective assessment of chronic stress with significant links to adverse cardiovascular outcomes, according to new research to be presented at the Radiological Society of North America (RSNA) annual meeting.

Combining AI advances and ergonomic innovation, the R20 ultrasound platform reportedly offers a variety of automated tools and design features to facilitate a smoother, efficient imaging workflow.

In MRI findings to be presented at the upcoming RSNA meeting, researchers demonstrated that the combination of higher muscle mass and lower visceral fat may have an impact on brain aging.

Geared toward interventional radiologists, the Alphenix 4D CT with Aquilion One/Insight Edition combines angiography capabilities with advanced features in computed tomography.

The latest update of the Cardiovascular Workspace software reportedly emphasizes secure cloud deployment and accelerated adoption of AI tools for increased efficiency.

In a recent interview, Timothy Fairbairn, Ph.D., and Fatima Rodiguez, M.D., discussed new research findings, recently presented at the American Heart Association (AHA) conference, showing the value of AI-powered quantification of plaque burden from CCTA exams for predicting adverse cardiovascular outcomes.

In a recent interview, Hari Kishan Gonuguntla, M.D., discussed AI-powered evaluation of chest X-rays with the Lung Nodule Malignancy Score software and key findings from multinational prospective research presented at the recent ESMO Congress 2025 meeting.

Use of the radiotherapeutic agent 177Lu-edotreotide (ITM-11) demonstrated significantly higher absorption in gastroenteropancreatic neuroendocrine tumors than normal organs along with a favorable safety profile, according to SPECT research recently presented at the European Association of Nuclear Medicine (EANM) conference.

Pluvicto in combination with the standard of care led to a 28 percent reduction in the risk of radiographic progression or death in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to results from the phase III PSMAddition trial presented at the European Society for Medical Oncology (ESMO) conference.

For patients with relapsing multiple sclerosis, switching from oral therapies to subcutaneous monthly administration of the anti-CD20 monoclonal antibody ofatumumab led to over a 98 percent reduction of Gd+ T1 lesions on MRI at 96 weeks.

Facilitating increased efficiency in radiation therapy planning, the new Rembra RT and Areta RT computed tomography platforms reportedly offer 4D CT capabilities and image reconstruction speeds up to 106 images per second.

Emphasizing enhanced connectivity, the latest version of the Intelligent Radiation Therapy (iRT) software may facilitate improved workflow efficiencies with the planning, performance and reporting for radiation therapy.

The AI-powered cardiovascular ultrasound device reportedly offers enhanced spatial and contrast resolution as well as bolstered 4D imaging that enables improved evaluation of cardiac function for a wide range of patients.

Combining advances in imaging quality with access to 26 FDA-cleared applications for automated and accelerated tasks, the Transcend Plus software will be featured at the upcoming European Society of Cardiology (ESC) and American Society of Echocardiography (ASE) conferences.

In the second part of a recent interview, Tammie Benzinger, M.D., Ph.D., discusses recently presented research from the Alzheimer’s Association International Conference (AAIC) that showed the ability of portable low-field MRI to detect mild and moderate amyloid-related imaging abnormalities (ARIAs).

The dose length product (DLP) for the flash mode on a dual-source photon-counting CT system was less than a third of that for the spiral mode, according to a study of CTA findings for 1,000 patients presented at the Society of Cardiovascular Computed Tomography (SCCT) conference.

In a recent interview, Amir Ahmadi, M.D., discussed limitations of conventional diagnostic assessments for people with suspected coronary artery disease, and the emergence of AI-enabled plaque quantification to facilitate more timely detection and intervention.

Catch up on recent interviews with Jean-Luc C. Urbain, M.D., Amir Iravani, M.D., Liza Lindenberg, M.D., and more faculty from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 conference.

In a recent interview at the SNMMI conference, Ryota Satoh, Ph.D., discussed new positron emission tomography (PET research examining the role of neuroinflammation in differentiating between progressive apraxia of speech (PAOS) and Parkinson-plus syndrome.

In a recent interview, Jean-Luc C. Urbain, M.D., Ph.D., the new president of the Society for Nuclear Medicine and Molecular Imaging, discussed current challenges in nuclear medicine and key goals, including improved access to nuclear medicine for people in underserved communities.

In a recent interview at the SNMMI conference Amir Iravani, M.D., discussed a new sub-analysis from the CONDOR study, which revealed consistently high positive predictive value for 18F-piflufolastat PSMA PET/CT in the detection of local prostate cancer recurrence.

In a recent interview at the SNMMI conference, Liza Lindenberg, M.D., discussed preliminary research findings that suggest the potential of the 18F-fluciclovine PET/CT for detection of multiple myeloma.

For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.